Jpmorgan Chase & CO Lucid Diagnostics Inc. Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 36,098 shares of LUCD stock, worth $38,985. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,098
Previous 36,098
-0.0%
Holding current value
$38,985
Previous $36,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding LUCD
# of Institutions
84Shares Held
31.4MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.52MShares$4.89 Million0.0% of portfolio
-
Masters Capital Management LLC Atlanta, GA4MShares$4.32 Million0.15% of portfolio
-
Two Seas Capital LP Rye, NY3MShares$3.24 Million0.06% of portfolio
-
Awm Investment Company, Inc. New York, NY2.99MShares$3.23 Million0.37% of portfolio
-
Ghisallo Capital Management LLC Greenwich, CT2.96MShares$3.2 Million0.33% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $41.7M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...